Lassa virus diversity and feasibility for universal prophylactic vaccine

Area of Science:

• * Virology and infectious diseases, focusing on Lassa virus (LASV).
• * Public health and vaccine development strategies.
• * Epidemiology of zoonotic viral diseases.

Background:

• * Lassa virus (LASV) is a prevalent mammarenavirus in West Africa, causing Lassa fever (LF) with significant morbidity and mortality.
• * The rodent host, *Mastomys natalensis*, maintains LASV, with recent evidence of geographic expansion.
• * LASV is recognized as a top-priority pathogen by the WHO, highlighting the urgent need for vaccines.

Purpose of the Study:

• * To review recent advancements in Lassa virus vaccine research and development.
• * To analyze the influence of LASV genetic and biological diversity on vaccine candidate design.
• * To assess progress towards meeting the World Health Organization's Target Product Profile (TPP) for an effective LASV vaccine.

Main Methods:

• * Comprehensive literature review of recent studies on Lassa virus vaccine development.
• * Analysis of LASV genetic and biological diversity data.
• * Evaluation of vaccine candidates against WHO TPP criteria.

Main Results:

• * Significant progress has been made in developing various LASV vaccine candidates.
• * LASV genetic and biological diversity presents challenges for broad vaccine efficacy.
• * Ongoing research aims to address these challenges to create effective LF vaccines.

Conclusions:

• * Developing a broadly protective Lassa virus vaccine requires careful consideration of viral diversity.
• * Continued research and development are crucial to meet the WHO's TPP for Lassa fever vaccines.
• * Addressing LASV's geographic expansion and public health impact remains a priority.